Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C Virus

• Status: Completed
• Trial end date: 2010-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the antiviral effect following three days of dosing with BMS-824393 in chronically genotype subtype 1a and 1b Hepatitis C virus (HCV) infected subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb

Criteria

Inclusion Criteria:

• Treatment naive chronically infected subjects with Hepatitis C Virus genotype 1

• HCV RNA viral load of ≤10*5* IU/mL (100,000 IU/mL)

• Body Mass Index (BMI) of 18 to 35 kg/m², inclusive

Exclusion Criteria:

• Women who are pregnant or breast feeding

• Any significant acute or chronic medical illness which is not stable or is not controlled with medication or is not consistent with Hepatitis C infection

• Any other medical, psychiatric and/or social reason which, in the opinion of the Investigator, would make the candidate inappropriate for participation in this study